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ABSTRACT
The development of rifaximin- and rifampicin-
resistant intestinal coliforms was studied in 27
subjects receiving rifaximin for 3 days by plating
stool samples on media containing rifaximin
200 mg ⁄L or rifampicin 64 mg ⁄L before treatment
(day 0), after treatment was completed (day 3), and
after a further 2 days (day 5). The susceptibility of
enterococci grown on day 0 and day 3 was also
studied in 71 subjects. Significant increases in
antimicrobial-resistant coliform flora were not seen
in either the rifaximin-treated or the placebo-
treated subjects. Enterococci recovered pre- and
post-treatment showed similar susceptibilities.
Rifaximin did not select for significant resistance
in the Gram-negative and Gram-positive intestinal
flora during therapy.
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The aim of this study was to determine whether
rifaximin, used for treatment of acute travellers’
diarrhoea, encouraged the development of rifax-
imin- and rifampicin-resistant Gram-negative
and Gram-positive faecal flora. College students
from the USA who suffered from diarrhoea in
Guadalajara, Mexico during the summer of 2000
were included in a placebo-controlled trial eval-
uating rifaximin treatment [1]. Stool samples
were collected from subjects receiving rifaximin
200 mg three times daily (600 mg ⁄day) for
3 days, rifaximin 400 mg three times daily
(1200 mg ⁄day) for 3 days, or a placebo for
3 days. Samples were collected immediately
before therapy (day 0), immediately after ther-
apy (day 3), and after a further 2 days (day 5),
and were investigated for resistant flora as
described previously [2].
Ten-fold dilutions (to 10)5) of samples from 27
patients were plated (100 lL) on to Mueller–
Hinton agar (Becton Dickinson, Sparks, MA,
USA) containing rifaximin (Salix Pharmaceuticals,
Raleigh, NC, USA) 200 mg ⁄L or rifampicin (Sig-
ma, St Louis, MO, USA) 64 mg ⁄L. Rifaximin
200 mg ⁄L was selected because this concentration
is eight-fold higher than the median MIC90 for
enteric pathogens, and is at the upper range of
susceptibility for any of the enteric bacterial
pathogens studied [3]. Rifampicin 64 mg ⁄L was
selected because this is the upper range of
susceptibility for Gram-positive and Gram-negat-
ive bacteria [4,5]. Following incubation over-
night at 37C, one colony of a Gram-negative
bacterium isolated on rifaximin- or rifampicin-
containing agar from each of three stool samples
(days 0, 3 and 5) ⁄patient (three colonies ⁄patient)
was identified with the API 20E system (bio-
Me´rieux, Marcy L’Etoile, France). MICs of rifax-
imin were determined [3] in the Houston
laboratory for one colony of Gram-negative bac-
teria ⁄ stool sample growing on either rifaximin or
rifampicin.
Enterococci were recovered from the day 0 and
day 3 samples taken from 71 patients by plating
on to Streptococcus faecalis medium (Bacto SF
Medium; Difco Laboratories, Detroit, MI, USA)
and Bacto Bile Esculin Agar (Difco), and incuba-
ting at 45.5C for 72 h. Putative colonies of
enterococci were transferred to storage media
stabs (BHI agar; Difco) and transported to Hous-
ton for further testing. Colonies isolated from
both pre- and post-treatment samples were tested
for susceptibility to rifaximin [3]. Differences in
numbers of rifaximin- or rifampicin-resistant col-
iforms, and differences in post-treatment vs.
pre-treatment susceptibilities of enterococci, were
compared between groups with Student’s t-test.
The numbers of rifaximin- and rifampicin-
resistant coliforms seen in the pre-treatment stool
sample and following treatment with rifaximin or
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placebo are shown in Fig. 1. Low numbers of
rifaximin- and rifampicin-resistant coliforms
were isolated from the initial stool sample in all
groups before treatment. Baseline pre-treatment
numbers of antimicrobial-resistant coliforms were
higher for the groups randomised to receive
1200 mg ⁄day and 600 mg ⁄day, compared with
the group randomised to receive a placebo, but
these differences were not significant (p 0.0683;
Wilcoxon Mann–Whitney test). Significant increa-
ses in the numbers of rifaximin- or rifampicin-
resistant coliforms were not found in the day 3
and day 5 post-treatment samples, compared
with the pre-treatment baseline samples for the
three groups. Similar values were seen for the
same subjects when stool samples were plated on
to rifampicin-containing medium.
Twenty-seven coliforms growing on rifaximin-
containing agar were identified biochemically as
Escherichia coli. These isolates did not show
increased resistance when pre-treatment stool
isolates were compared with post-treatment iso-
lates in the three groups. The MIC90 for coliforms
growing on rifaximin- or rifampicin-containing
media from pre-treatment (day 0) and post-
treatment (days 3 and 5) stools was 64 mg ⁄L for
subjects randomised to receive either of the two
doses of rifaximin (range 1–128 mg ⁄L) or for
subjects in the placebo group (range 2–128 mg ⁄L).
Enterococci were isolated from pre-treatment
and post-treatment samples at similar frequencies
(10 ⁄ 24 vs. 20 ⁄ 24 for the 1200 mg ⁄day group; 9 ⁄ 23
vs. 18 ⁄ 23 for the 600 mg ⁄day group; 8 ⁄ 24 vs.
17 ⁄ 24 for the placebo group). In total, enterococci
were recovered from both pre- and post-treat-
ment stool samples for 27 (38%) of 71 patients.
MICs of enterococci were £ 64 mg ⁄L for rifaximin
and £ 16 mg ⁄L for rifampicin. No significant
changes in susceptibility were seen between the
pre-treatment and post-treatment samples.
Rifaximin is a poorly absorbed rifamycin deriv-
ative showing bactericidal activity against a broad
range of enteric pathogens [3,6]. Rifaximin is
available in several countries in Europe, Asia and
Latin America for the treatment of bacterial diar-
rhoea [7]. It has also been used for the treatment of
small-bowel bacterial overgrowth syndrome [8],
hepatic encephalopathy [9], and diverticular dis-
ease of the colon, as well as for preventing infec-
tious complications in colorectal surgery [7]. A
paediatric suspension of this drug has been devel-
oped for children with bacterial diarrhoea [10].
Although the development of resistance is a
major concern when rifamycins are used for
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Fig. 1. Numbers of faecal rifaximin- and rifampicin-resist-
ant coliforms (GNB) isolated pre-treatment (day 0), imme-
diately post-treatment (day 3) and 2 days post-treatment
(day 5) from patients treated for 3 days with either
rifaximin 1200 mg ⁄day, rifaximin 600 mg ⁄day or placebo.
Table 1. Rifaximin and rifampicin MICs (mg ⁄L) for en-
terococci recovered before and after therapy for 3 days
with one of two doses of rifaximin or a placebo
Treatment groups
Rifaximin 600 mg Rifaximin 1200 mg Placebo
Number of patients 23 24 24
Enterococci from
paired faecal
samples
9 (39%) 10 (42%) 8 (33%)
Rifaximin MIC range
Day 0 8–64 8–64 8–64
Day 3 8–64 8–64 4–64
Rifaximin MIC50
Day 0 16 32 16
Day 3 16 32 32
Rifaximin MIC90
Day 0 64 64 64
Day 3 64 64 64
Rifampicin MIC range
Day 0 1–16 0.25–8 0.25–8
Day 3 1–16 0.5–8 0.25–8
Rifampicin MIC50
Day 0 2 2 4
Day 3 2 2 4
Rifampicin MIC90
Day 0 16 2 8
Day 3 16 2 8
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therapy, rifaximin did not select for significant
resistance among gut flora when given for 3 days.
It is unlikely that rifaximin would stimulate the
development of rifampicin-resistant Mycobacteri-
um tuberculosis, since the drug remains largely in
the gut during short-term use for the treatment of
diarrhoea. Extra-intestinal tissues infected with
M. tuberculosis should not be exposed to signifi-
cant concentrations of the drug, and growth of
M. tuberculosis on media containing varying con-
centrations of rifaximin does not lead to the
selection of rifampicin-resistant strains [11].
In summary, rifaximin appears to be a suitable
drug for the management of travellers’ diarrhoea
[12] and other non-systemic, non-dysenteric en-
teric bacterial infections. This drug has now been
licensed for use in the USA.
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Production by Escherichia coli isolates of
siderophore and other virulence factors and
their pathogenic role in a cutaneous
infection model
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ABSTRACT
Escherichia coli isolates from urinary tract infec-
tions (UTIs) (n = 124), extra-urinary sites (n = 37)
and normal faecal samples (n = 51) were exam-
ined for the presence of virulence factors, inclu-
ding siderophores (aerobactin and enterobactin).
The proportion of aerobactin producers was
significantly higher in UTI (69.4%; p 0.001) and
extra-urinary samples (70.3%; p 0.007) than in
controls (41.2%), while the proportion of ente-
robactin producers was significantly lower in the
UTI samples than in the controls (p 0.027). In a
cutaneous infection model, aerobactin-positive
E. coli showed more growth than non-aerobactin
and non-enterobactin isolates, even when other
virulence factors were identical.
Keywords Aerobactin, cutaneous infection model,
enterobactin, Escherichia coli, siderophore, virulence
factors
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